We thus hypothesized that hepatic ALS-L1023 actions would alleviate obesity, insulin resistance, and impaired glucose metabolism in part through PPARα-mediated hepatic lipid reductions. Here, PPARA is linked to obesity due to melanocortin 4 receptor deficiency.